Our results provide new insights into the dysregulated lnc-ATB/miR-200b/Kindlin-2 axis in the development of ESCC and suggest that lnc-ATB represent a potential therapeutic target for ESCC. The gene discussed is FERMT2; the disease is esophageal squamous cell carcinoma.